FDAnews
www.fdanews.com/articles/101720-epicept-dpn-trial-fully-enrolled

EpiCept DPN Trial Fully Enrolled

December 3, 2007

EpiCept has completed patient enrollment in the Phase IIb trial for topical EpiCept NP-1 cream for the treatment of pain of diabetic peripheral neuropathy (DPN).

The four-week, 200-patient trial will compare the active ingredients in NP-1 — 4 percent amitriptyline and 2 percent ketamine — against placebo.

The primary endpoint is the difference between changes in pain intensity from baseline compared with the average over the last seven days of treatment.

Jack Talley, EpiCept’s president and CEO, said the company expects top-line results in early 2008.